Exact Mass: 362.1986

Exact Mass Matches: 362.1986

Found 48 metabolites which its exact mass value is equals to given mass value 362.1986, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

Benzetimide

3-(1-benzylpiperidin-4-yl)-6-hydroxy-3-phenyl-2,3,4,5-tetrahydropyridin-2-one

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

phenaziterpene B

phenaziterpene B

C23H26N2O2 (362.1994)


   

isoleucylcysteyllysine

isoleucylcysteyllysine

C15H30N4O4S (362.1988)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)

(4R,4R)-2,2-(PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE)

C23H26N2O2 (362.1994)


   

solifenacin

solifenacin

C23H26N2O2 (362.1994)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist with pKis of 7.6, 6.9 and 8.0 for M1, M2 and M3 receptors, respectively.

   

4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE

4,4-DIISOCYANATO-3,3,5,5-TETRAETHYLDIPHENYLMETHANE

C23H26N2O2 (362.1994)


   

Dexetimide

benzetimide

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists Dexetimide ((+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide) is a piperidine anticholinergic and a high-affinity muscarinic receptor antagonist. Dexetimide can be used in studies of parkinson's disease[1][2].

   

2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-

2,8-Diazaspiro[5.5]undecane-1,7-dione, 2,8-bis(phenylmethyl)-

C23H26N2O2 (362.1994)


   

benzetimide

benzetimide

C23H26N2O2 (362.1994)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

   

5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol

5-(Phenylmethoxymethyl)-7-(1-piperidinylmethyl)-8-quinolinol

C23H26N2O2 (362.1994)


   

(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester

(4S)-4-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester

C23H26N2O2 (362.1994)


   

N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine

N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine

C15H30N4O4S (362.1988)


   
   
   

1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine

1-[(4-Chlorophenyl)-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-4-methylpiperazine

C18H27ClN6 (362.1986)


   

1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6S,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H26N2O2 (362.1994)


   

1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aS,4R,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-phenyl-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-2-cyclopropylethanone

C23H26N2O2 (362.1994)


   

(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

(6R,7S,8R)-4-benzyl-8-(hydroxymethyl)-7-[4-[(E)-prop-1-enyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C23H26N2O2 (362.1994)


   
   
   
   
   
   
   
   
   
   
   

Levetimide

Levetimide

C23H26N2O2 (362.1994)


Levetimide is a potent and stereoselective inhibitor of [3H](+)pentazocine binding, with a Ki of 2.2 nM[1].

   

1-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-6-methoxyphenazine

1-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]-6-methoxyphenazine

C23H26N2O2 (362.1994)


   

1-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-methoxyphenazine

1-{[(2e)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-6-methoxyphenazine

C23H26N2O2 (362.1994)